May. 13 at 6:58 AM
$MNKD On May 7, 2026, Wells Fargo raised the firm’s price target on MannKind Corporation (NASDAQ:MNKD) to
$10 from
$8 while maintaining an Overweight rating following disclosure of the company’s involvement with ralinepag DPI and ahead of upcoming PDUFA decisions tied to Afrezza and Furoscix. The firm said it now sees multiple potential avenues for revenue growth.
Similarly, H.C. Wainwright raised its price target on MannKind Corporation (NASDAQ:MNKD) to
$10 from
$8 while maintaining a Buy rating. The firm said Q1 results came in below expectations, though that does not alter its broader investment thesis, which is increasingly centered on the durability and upside potential of MannKind’s royalty and collaboration revenue streams. H.C. Wainwright also cited potential pipeline upside in support of the target increase.
